Skip to search formSkip to main contentSkip to account menu

VIM-D protocol

Known as: VIM-D Regimen, VIMD Regimen, VP16-Ifosfamide-Mitoxantrone-Dexamethasone Regimen 
A regimen consisting of etoposide, ifosfamide, mitoxantrone and dexamethasone used for treatment of relapsed or refractory Hodgkin's Lymphoma.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Benedikt’s syndrome (BS) is caused by the lesion in the midbrain and specifically manifests a series of symptoms, including… 
2014
2014
A sizable proportion of medication refractory tremor patients may not respond satisfactorily to deep brain stimulation (DBS) to… 
2011
2011
Cupric ion-chelated poly(hydroxyethyl methacrylate-n-vinyl imidazole) (poly(HEMA-VIM)) microspheres prepared by suspension… 
2004
2004
SummaryA total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16… 
Highly Cited
1987
Highly Cited
1987
Eight new cases (five adults and three children) of acute leukemia characterized by the presence in bone marrow cells of a t(4;11… 
1976
1976
After the stereotactic treatment of patients with Parkinson's disease, a correlative study between the site of the deep…